losoxantrone

structure given in first source

Also Known As:

7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one; Biantrazole; CI 941; CI-941; DUP-941; DuP 941; NSC 357885; PD 113785; anthrapyrazolone

Networked: 26 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ratain, M J: 2 articles (02/2002 - 02/2001)
2.	Vokes, E E: 2 articles (02/2002 - 02/2001)
3.	Finizio, M: 2 articles (02/2001 - 04/2000)
4.	Chen, Shujuan: 1 article (01/2021)
5.	Fan, Yunpeng: 1 article (01/2021)
6.	Fu, Wen: 1 article (01/2021)
7.	Liu, Jinhui: 1 article (01/2021)
8.	Liu, Shaojun: 1 article (01/2021)
9.	Liu, Wenbin: 1 article (01/2021)
10.	Peng, Liangyue: 1 article (01/2021)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/1993 - "Among three compounds entered it is of note that CI-941 has demonstrated an excellent activity against advanced breast cancer." 12/01/1991 - "One of these agents, CI-941, has been reported to have significant clinical activity in breast cancer. " 06/01/1991 - "CI-941 has shown significant activity in patients with advanced breast cancer and these agents appear to have a bright future." 05/01/1995 - "A 42-year-old woman with metastatic breast carcinoma treated with only DuP-941 developed, and died of, heart failure for which no other explanation was apparent. " 06/01/1999 - "Losoxantrone, an anthrapyrazole in clinical development, has shown promising single-agent activity in metastatic breast cancer. "
2.	Leukemia P388 12/31/1998 - "At their optimal dosages, congeners 13a-c, 13f, 13n, 13q, 13x, and 13dd were highly effective against P388 leukemia with T/C% of 200-381, while the T/C% value of DuP-941 was 147. "
3.	Carcinoma (Carcinomatosis) 01/01/2001 - "BBR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). " 01/01/2001 - "The novel 9-aza-anthrapyrazole BBR 3438 was significantly more effective than doxorubicin and losoxantrone (DuP-941) in two of the three tested prostate carcinoma models. "
4.	Neoplasms (Cancer) 04/01/2002 - "In contrast to these results, human tumor HepG2 cells did not show any CI-941 biotransformation after incubation." 02/01/2001 - "Collectively, these data indicate that fecal excretion of unmetabolized drug via biliary and/or intestinal excretion is the primary pathway of intravenously administered losoxantrone elimination in cancer patients with refractory solid tumors." 02/01/2001 - "Elimination pathways of [14C]losoxantrone in four cancer patients." 01/01/1998 - "This work sought to assess the sensitivity and selectivity of UV spectral matching for monitoring the impurity profile of drugs, using as an illustration DuP 941, an anti-cancer drug under development. " 03/01/1998 - "SCCA tumor transplants injected with 240 microg/gm CI-941 followed after 4 hours by ILT with the KTP532 laser led to a complete response rate of 72% (21/29) compared with 45% (13/29) for ILT alone. "
5.	Prostatic Neoplasms (Prostate Cancer) 04/01/2000 - "A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer." 04/01/2000 - "Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients with metastatic hormone-refractory prostate cancer. " 04/01/2000 - "Patients with metastatic prostate cancer progressing on androgen ablation therapy without demonstrable antiandrogen withdrawal response were treated with losoxantrone 50 mg/m2 i.v. bolus every 21 days. "

Related Drugs and Biologics

1.	anthrapyrazole
2.	Paclitaxel (Taxol)
3.	Doxorubicin (Adriamycin)
4.	Vinorelbine (Navelbine)
5.	BBR 3438
6.	Hormones (Hormone)
7.	pyrazolanthrone
8.	losoxantrone
9.	Anthracyclines
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Lasers (Laser)
4.	Injections